France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts

Mar.10
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.

Key Points

 

HAS confirmation: France’s national health authority (Haute Autorité de Santé, HAS) confirmed to 2Firsts that updated smoking-cessation guidelines will address the role of e-cigarettes.

 

Timeline: The revised national cessation recommendations are currently under preparation and are expected to be published by the end of 2026.

 

Scope of guidance: HAS said the recommendations will focus on clinical and public-health considerations rather than establishing technical standards for vaping products.

 

Evidence limits: The agency noted that existing scientific studies remain insufficient to clearly assess the risks and benefits across different categories of vaping products.

 

Policy context: HAS said it is monitoring European regulatory developments and will consider them if they affect the guideline update.

 


 

2Firsts

March 10, 2026

 

France’s national health authority will address the role of e-cigarettes in updated smoking-cessation guidelines expected by the end of 2026, the agency told 2Firsts in response to questions about the ongoing revision of its national recommendations.

 

The Haute Autorité de Santé (HAS) said the updated recommendations on smoking cessation are currently under preparation and are scheduled for publication at the end of 2026. In its response to questions from 2Firsts, the agency said the working group responsible for the revision will examine “the place of e-cigarettes in the smoking-cessation process.”

 

The forthcoming document will update France’s 2014 national recommendations on tobacco cessation, which guide healthcare professionals in primary care on screening, treatment pathways and the maintenance of abstinence among smokers.

 

Guideline Update Underway

 

According to HAS, the revision of the cessation guidelines remains ongoing and the authority is not yet in a position to present final conclusions. The publication of the updated recommendations is planned for the end of 2026.

 

When asked whether vaping remains part of the scope of the guideline review, the agency confirmed that the topic continues to be included in the work currently being carried out.

 

“We will address the place of electronic cigarettes in the smoking-cessation process,” the HAS press office said in its written response to 2Firsts.

 

The agency did not indicate what conclusions the final recommendations might reach regarding the use of vaping products in cessation pathways.

 

No Technical Standards Planned

 

HAS also said the guideline update will not establish technical or product-level standards for vaping devices or e-liquids.

 

Responding to questions about potential methodological criteria for evaluating vaping products — such as emissions measurements, exposure levels or device quality standards — the agency said these issues fall outside the scope of the recommendations currently under preparation.

 

“This question is not included in the framing document and this type of work does not fall within the remit of the professional department responsible for the guidelines,” the agency said.

 

The recommendations therefore focus on clinical and public-health considerations rather than technical product regulation, according to HAS.

 

Evidence Gaps on Product Categories

 

HAS said differentiating between categories of vaping products remains difficult given the current scientific evidence base.

 

The agency said that while such differentiation could be desirable, it is challenging in practice because vaping technologies are evolving rapidly and existing research remains limited.

 

“Vaping products are constantly evolving and studies by category of vaping products are insufficient in number to precisely describe the benefits and risks of each type of product,” HAS said.

 

As a result, the working group responsible for the guideline revision may recommend further research in this area.

 

Monitoring EU Regulatory Developments

 

The agency also confirmed that it is monitoring regulatory developments at the European level related to tobacco and vaping products.

 

HAS said that if changes in European regulation affect its work, they will be taken into account in the guideline update.

 

European institutions are currently reviewing several elements of nicotine product regulation, including potential revisions to the Tobacco Products Directive and other related regulatory frameworks.

 

Scientific Context

 

France’s national health and safety agency, the Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail (ANSES), published a scientific assessment in February 2026 concluding that vaping is less harmful than combustible tobacco but not risk-free.

 

The report reviewed available epidemiological and toxicological evidence and concluded that the absence of combustion significantly reduces exposure to many toxic substances compared with cigarette smoke, while emphasizing that scientific uncertainties remain regarding long-term health effects.

 

ANSES provides scientific risk assessments to inform public policy, while HAS is responsible for issuing clinical and public-health recommendations, including guidance related to smoking cessation.

 

Outlook

 

France’s updated cessation recommendations are expected to address how vaping products may be considered within the country’s clinical approach to tobacco dependence, though the authority has not indicated what conclusions the final document will reach.

 

For continued coverage of European regulatory developments related to vaping and nicotine products, follow reporting from 2Firsts.

 

Cover image generated by AI.


Further reading:

 

2FIRSTS | France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
2FIRSTS | France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
www.2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.
Sep.03